David Weiner - Inovio Pharmaceuticals Director
| INO Stock | USD 10.02 0.34 3.51% |
Director
Dr. David B. Weiner Ph.D., is the Director of Inovio Pharmaceuticals Inc. Dr. Weiner joined The Wistar Institute in 2016, the nations first independent biomedical research institute, NCIdesignated Cancer Center, and an international leader in cancer, immunology and infectious disease research, as Executive Vice President, Director of its Vaccine Center, and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research. Previously, Dr. Weiner was Professor of Pathology Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the Universitys Perelman School of Medicine. In scientific circles, Dr. Weiner is known as the father of DNA vaccines. He has more than 350 peerreviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and was designated by the Institute for Scientific Information as one of the topcited scientists in the world. An inventor of more than 100 issued and pending US patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Directors Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Childrens Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy since 2016.
| Age | 62 |
| Tenure | 8 years |
| Address | 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 |
| Phone | 267 440 4200 |
| Web | https://www.inovio.com |
David Weiner Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Weiner against Inovio Pharmaceuticals stock is an integral part of due diligence when investing in Inovio Pharmaceuticals. David Weiner insider activity provides valuable insight into whether Inovio Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Inovio Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Inovio Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Weiner over a year ago Exercise or conversion by David Weiner of 11666 shares of Inovio Pharmaceuticals subject to Rule 16b-3 |
Inovio Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.3211) % which means that on every $100 spent on assets, it lost $0.3211. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7955) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals' management efficiency ratios could be used to measure how well Inovio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -1.09. At this time, Inovio Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 23rd of April 2024, Other Current Assets is likely to grow to about 6.9 M, while Total Assets are likely to drop about 131.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Richard | Vaxart Inc | 58 | |
| Timothy Block | Hepion Pharmaceuticals | 61 | |
| Rachel King | Novavax | 58 | |
| Philip Vickers | AVROBIO | 58 | |
| Arnold Lippa | Hepion Pharmaceuticals | 70 | |
| Rajiv Modi | Novavax | 56 | |
| Geoffrey Cox | Vaxart Inc | 71 | |
| Jan Leschly | Vaxart Inc | 77 | |
| Annalisa Jenkins | AVROBIO | 51 | |
| Ian Clark | AVROBIO | 57 | |
| Michael McManus | Novavax | 74 | |
| Phillip Donenberg | AVROBIO | 57 | |
| Michael Finney | Vaxart Inc | 65 | |
| Richard Markham | Vaxart Inc | 65 | |
| Richard Douglas | Novavax | 64 | |
| Anne VanLent | Vaxart Inc | 69 | |
| Michael Dougherty | Vaxart Inc | 58 | |
| Gail Boudreaux | Novavax | 55 | |
| Christopher Paige | AVROBIO | 64 | |
| John Brancaccio | Hepion Pharmaceuticals | 69 | |
| MD FACP | Hepion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.32 |
Inovio Pharmaceuticals Leadership Team
Elected by the shareholders, the Inovio Pharmaceuticals' board of directors comprises two types of representatives: Inovio Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inovio. The board's role is to monitor Inovio Pharmaceuticals' management team and ensure that shareholders' interests are well served. Inovio Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inovio Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Bagarazzi, Chief Medical Officer | ||
| Mort Collins, Independent Director | ||
| Asli Gevgilili, Chief Officer | ||
| MBA MA, Senior Development | ||
| Adel Mahmoud, Independent Director | ||
| Wendy Yarno, Director | ||
| Ben Matone, Director Relations | ||
| Morton Collins, Independent Director | ||
| Thomas Hong, Manager Relations | ||
| Nancy Wysenski, Director | ||
| Daniel Jordan, VP Operations | ||
| Ann Miller, Director | ||
| Peter Kies, Chief Officer | ||
| Avtar Dhillon, Non-Executive Chairman of the Board | ||
| George Bickerstaff, Director | ||
| Lota Zoth, Director | ||
| Simon Benito, Independent Director | ||
| Jeffrey Skolnik, Senior Development | ||
| Niranjan Sardesai, COO | ||
| Robert Juba, Senior Management | ||
| E MBA, Senior Assurance | ||
| Joseph Kim, CEO and President Director and Member of Fin. Committee | ||
| Jong Kim, President CEO, Director | ||
| Laurent Humeau, Chief Scientific Officer | ||
| Angel Cabrera, Independent Director | ||
| David Weiner, Director | ||
| Robert JD, General Officer | ||
| Jacqueline Shea, President CEO | ||
| PE MBA, Senior Development |
Inovio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inovio Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (266.86) % | ||||
| Current Valuation | 111.14 M | ||||
| Shares Outstanding | 25.91 M | ||||
| Shares Owned By Insiders | 1.48 % | ||||
| Shares Owned By Institutions | 16.66 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 2.20 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Inovio Stock analysis
When running Inovio Pharmaceuticals' price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.09) | Revenue Per Share 0.038 | Quarterly Revenue Growth (0.18) | Return On Assets (0.32) | Return On Equity (0.80) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.